As weight loss tablets move closer to launch, we wanted to understand how aware people already are of this new option
Purpose-built for physicians Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits Key takeaways: Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model
Compounded semaglutide may be a good option for patients who: Cannot access name brand medication due to shortages and supply disruptions
The following will review recent evidence, including from the FLOW and SELECT trials, disclosing benefits of GLP-1 RAs, with a particular focus on kidney disease progression and cardiovascular benefits in patients with diabetes
Every story is crafted to inform, engage, and reflect whats capturing attention across America.Read More
Glutathione IV therapy will help to prevent the development and progression of neurodegenerative diseases and support overall brain health and functioning
